| 2026-09-01 | 8-K | Form 8-K, Item 8.01 |
| 2026-08-14 | Deck | Alumis Corporate Presentation - August 2026 |
| 2026-08-13 | Press release | Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements |
| 2026-08-13 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-13 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-10 | Press release | PDF Version |
| 2026-08-10 | Press release | Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Report · Q3 2026 |
| 2026-08-10 | 8-K | Form 8-K, Item 8.01 |
| 2026-07-02 | 8-K | Form 8-K, Item 5.07 |
| 2026-06-29 | 8-K | Form 8-K, Item 8.01 |
| 2026-05-18 | Proxy | Definitive proxy statement |
| 2026-05-14 | Press release | Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements |
| 2026-05-14 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-14 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-03-30 | Deck | Envudeucitinib ONWARD1 and ONWARD2 Phase 3 Data Presentation |
| 2026-03-30 | 8-K | Form 8-K, Item 8.01 |
| 2026-03-28 | Press release | PDF Version |
| 2026-03-28 | Press release | Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms |
| 2026-03-19 | Press release | Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements |
| 2026-03-19 | Press release | Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements |
| 2026-03-19 | 8-K | Form 8-K, Item 2.02 results |
| 2026-03-19 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-03-18 | Press release | Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting |
| 2026-03-18 | Press release | Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasi |
| 2026-03-02 | Press release | PDF Version |
| 2026-03-02 | Press release | Alumis to Present at the Leerink Partners Global Healthcare Conference |
| 2026-02-05 | Press release | Alumis to Participate in Upcoming February Investor Conferences |
| 2026-01-09 | Press release | PDF Version |
| 2026-01-09 | Press release | Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Sha |
| 2026-01-09 | 8-K | Form 8-K, Item 2.02 results |
| 2026-01-07 | Press release | PDF Version |
| 2026-01-07 | Press release | Alumis Announces Pricing of Upsized Public Offering of Common Stock |
| 2026-01-06 | Deck | Alumis Envudeucitinib ONWARD Phase 3 Plaque Psoriasis Trial Results Event Presentation |
| 2026-01-06 | Press release | PDF Version |
| 2026-01-06 | Press release | PDF Version |
| 2026-01-06 | Press release | Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 |
| 2026-01-06 | Press release | Alumis Announces Proposed Public Offering of Common Stock |
| 2026-01-06 | 8-K | Form 8-K, Item 8.01 |
| 2026-01-05 | Press release | PDF Version |
| 2026-01-05 | Press release | Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Sever |